Sanofi Starts Selling Diabetes Treatment Soliqua in U.S.
January 04 2017 - 2:14AM
Dow Jones News
By Inti Landauro
PARIS--French drug giant Sanofi SA (SAN.FR) said Wednesday it
started selling in the U.S. a new diabetes treatment called
Soliqua, a combination of drugs glargine and lixisenatide, as part
of efforts to offset an expected decline in revenue from the loss
of patent protection for its Lantus insulin treatment.
The new treatment has demonstrated more efficiency than Lantus,
Sanofi said.
Soliqua is a combination of two drugs already on the market,
including Lantus. Sanofi says a single daily dose of the mix will
allow a patient to improve the control of glycemia level.
The new treatment was approved by the U.S. Food and Drug
Administration late last year.
Sanofi is one of the world's largest maker of diabetes drugs,
though its business is under pressure as health-care systems get
more cost-conscious and competition increases.
Write to Inti Landauro at inti.landauro@wsj.com
(END) Dow Jones Newswires
January 04, 2017 01:59 ET (06:59 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024
